ABBO News has recently covered a really exciting news on ImmunityBio.
ImmunityBio is a biotechnology company that focuses on developing innovative immunotherapies.
Edward Cooke the financial analyst wrote that ImmunityBio’s stock (NASDAQ: IBRX) has experienced a remarkable shift of over 30% in the early trading hours on Monday, April 29th, 2024.
This biggest change and increase in stock was driven by the release of promising overall survival results from the company’s clinical trial, QUILT 3.055, which evaluated the efficacy of its immunotherapy drug, Anktiva, in treating non-small cell lung cancer (NSCLC).
The QUILT 3.055 clinical trial enrolled patients diagnosed with advanced-stage non-small cell lung cancer (NSCLC) that had worsened after treatment by a checkpoint inhibitor and standard of care chemotherapy. Anktiva was given to these particular personnels combined with any of the specific checkpoint inhibitor they have used initially observed. It is worth noting that when they were used together, there was a significant increase in life expectancy among this cohort of patients.
ImmunityBio says that Anktiva has shown good results in NSCLC patients who are either PD-L1 negative or PD-L1 positive, indicating that it could help many different kinds of patients. Anktiva is an IL-15 agonist immunotherapy that stimulates the release of natural killer cells and killer T-cell mediated cytotoxicity by cells in the body which fight against the tumor cells more efficiently.
The data strongly supports the rule of action involving Anktiva as an immune-enhancer capable of stimulating natural killer cells and memory T cells, thereby potentially saving those patients who did not respond to the checkpoint inhibitor treatment in several kinds of cancer, the organization said.
ImmunityBio has scheduled a pivotal meeting with the U.S. Food and Drug Administration (FDA) in June. This is following encouraging results from the previous trials. In this meeting, the discussions will revolve around registration filing for Anktiva in combination with checkpoint inhibitors for second and third-line NSCLC patients who did not respond to checkpoint therapy previously.
In addition, the U.S. health regulator cleared ImmunityBio’s Anktiva-Bacillus Calmette-Guérin combination therapy for a certain type of bladder cancer last week, showing more uses of Anktiva in cancer variations.
ABBO Experts says ImmunityBio is also planning to conduct a conference call to discuss registration plans for NSCLC and to provide updates on the readiness of the Anktiva launch for non-muscle invasive bladder cancer. It is expected that the first shipments of Anktiva vials will be made available from the week beginning May 6, 2024.
At the time of ABBO News’ report, IBRX stock was trading at $9.86, showing a remarkable 34.13% increase from the previous trading session.
About ABBO News
ABBO News is a leading platform dedicated to providing timely and insightful stock news and analysis. With a team of seasoned financial journalists and market analysts, ABBO News diligently examines the financial markets to deliver up-to-the-minute updates on a wide range of topics, including stocks, market trends, company earnings, mergers and acquisitions, initial public offerings (IPOs), and various other market-related developments.
Understanding the importance of real-time information in today’s dynamic markets, ABBO News’ dedicated team works tirelessly to deliver breaking news as it happens, allowing readers to stay ahead of the curve and make informed decisions based on the most recent developments.
Pin ABBO News website on your browsers and stay updated with insightful stock market news!